ImmunityBio (IBRX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $10.00, +0.91% vs the prior close of $9.91.
- Volume 19.90M shares, 1.8x its 50-day average.
- New SEC filings: 8-K (Oct 14, 2026).
- No new insider buys or sales reported since the prior session.
IBRX rises 0.9% to $10.00. Closed at $10.00, +0.91% vs the prior close of $9.91. Day range $9.81–$10.50, opened at $10.20.
IBRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — IBRX rises 0.9% to $10.00
- Closed at $10.00, +0.91% vs the prior close of $9.91. Day range $9.81–$10.50, opened at $10.20.
- Volume was 19.90M shares, 1.8x its 50-day average of 11.14M.
- Price is +17.3% vs its 50-day average ($8.52) and +32.3% vs its 200-day average ($7.56).
- 52-week range $1.95–$12.43; today's close sits at 77% of that range, 19.5% below the 52-week high.
Oct 14, 2026 — IBRX rises 1.1% to $9.91 on 2.8x normal volume
- Closed at $9.91, +1.12% vs the prior close of $9.80. Day range $9.35–$10.45, opened at $9.69.
- Volume was 30.23M shares, 2.8x its 50-day average of 10.91M — unusually heavy trading.
- Price is +17.0% vs its 50-day average ($8.47) and +31.8% vs its 200-day average ($7.52).
- 52-week range $1.95–$12.43; today's close sits at 76% of that range, 20.3% below the 52-week high.
- SEC filings that day: 8-K.
Oct 13, 2026 — IBRX slides 3.2% to $9.80
- Closed at $9.80, -3.16% vs the prior close of $10.12. Day range $9.56–$10.06, opened at $10.00.
- Volume was 11.60M shares, 1.1x its 50-day average of 10.86M.
- Price is +16.5% vs its 50-day average ($8.41) and +31.0% vs its 200-day average ($7.48).
- 52-week range $1.95–$12.43; today's close sits at 75% of that range, 21.2% below the 52-week high.
Oct 12, 2026 — IBRX slides 3.7% to $10.12
- Closed at $10.12, -3.71% vs the prior close of $10.51. Day range $10.05–$10.62, opened at $10.59.
- Volume was 11.06M shares, 1.0x its 50-day average of 10.82M.
- Price is +21.1% vs its 50-day average ($8.36) and +36.0% vs its 200-day average ($7.44).
- 52-week range $1.95–$12.43; today's close sits at 78% of that range, 18.6% below the 52-week high.
Oct 9, 2026 — IBRX jumps 6.1% to $10.51, a 6-month high, 3 up days in a row
- Closed at $10.51, +6.05% vs the prior close of $9.91. Day range $9.87–$10.80, opened at $9.95.
- Volume was 18.66M shares, 1.7x its 50-day average of 10.67M.
- Price is +26.7% vs its 50-day average ($8.30) and +42.0% vs its 200-day average ($7.40).
- 52-week range $1.95–$12.43; today's close sits at 82% of that range, 15.4% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — IBRX rises 1.6% to $9.91
- Closed at $9.91, +1.64% vs the prior close of $9.75. Day range $9.43–$10.05, opened at $9.63.
- Volume was 10.49M shares, 1.0x its 50-day average of 10.64M.
- Price is +20.3% vs its 50-day average ($8.24) and +34.6% vs its 200-day average ($7.36).
- 52-week range $1.95–$12.43; today's close sits at 76% of that range, 20.3% below the 52-week high.
Oct 7, 2026 — IBRX rises 0.6% to $9.75
- Closed at $9.75, +0.62% vs the prior close of $9.69. Day range $9.33–$9.93, opened at $9.50.
- Volume was 11.78M shares, 1.1x its 50-day average of 10.64M.
- Price is +19.3% vs its 50-day average ($8.17) and +33.1% vs its 200-day average ($7.32).
- 52-week range $1.95–$12.43; today's close sits at 74% of that range, 21.6% below the 52-week high.
Oct 6, 2026 — IBRX slides 6.6% to $9.69
- Closed at $9.69, -6.65% vs the prior close of $10.38. Day range $9.61–$10.36, opened at $10.32.
- Volume was 16.89M shares, 1.6x its 50-day average of 10.51M.
- Price is +19.4% vs its 50-day average ($8.12) and +33.0% vs its 200-day average ($7.28).
- 52-week range $1.95–$12.43; today's close sits at 74% of that range, 22.0% below the 52-week high.
Oct 5, 2026 — IBRX rises 0.9% to $10.38, a 6-month high
- Closed at $10.38, +0.92% vs the prior close of $10.28. Day range $10.12–$10.81, opened at $10.76.
- Volume was 16.87M shares, 1.6x its 50-day average of 10.34M.
- Price is +28.7% vs its 50-day average ($8.06) and +43.2% vs its 200-day average ($7.25).
- 52-week range $1.95–$12.43; today's close sits at 80% of that range, 16.5% below the 52-week high.
Oct 2, 2026 — IBRX jumps 10.8% to $10.28, a 6-month high on 3.2x normal volume
- Closed at $10.28, +10.83% vs the prior close of $9.28. Day range $9.39–$10.55, opened at $9.39.
- Volume was 31.25M shares, 3.2x its 50-day average of 9.84M — unusually heavy trading.
- Price is +28.6% vs its 50-day average ($8.00) and +42.7% vs its 200-day average ($7.21).
- 52-week range $1.95–$12.43; today's close sits at 80% of that range, 17.3% below the 52-week high.
IBRX latest news & SEC filings
Every SEC filing by or about IBRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Oct 6, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 6, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 5, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 2, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 6, 2026 · SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $51.24M (prior year $26.43M) (+93.9% vs Jun 30, 2025)
- Net income: -$230.38M (prior year -$92.56M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.22 (prior year -$0.10) (loss widened vs Jun 30, 2025)
Aug 4, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 30, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 6, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cohen Cheryl sold 131,210 shares at $9.50 (≈$1.25M) on Jul 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 6, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Selecky Christobel sold 159,478 shares at $9.02 (≈$1.44M) on Jul 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade IBRX
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Apr 9, 2026, Feb 23, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.44% (largest 10.8%). That is a volatile stock.
- Liquidity: about 15.88M shares (≈$158.83M) trade per day on average.
- 52-week position: $10.00 vs a range of $1.95–$12.43 (77% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 14 sales; latest: Cheryl Cohen sold 131,210 shares on Jul 2, 2026.
- Latest filings: 8-K Oct 14, 2026; 10-Q Aug 4, 2026; 8-K Aug 4, 2026.
- Share count: 1.06B shares outstanding (Jul 31, 2026), +12.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
IBRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 10.20 | 10.50 | 9.81 | 10.00 | 19.90M |
| Oct 14, 2026 | 9.69 | 10.45 | 9.35 | 9.91 | 30.23M |
| Oct 13, 2026 | 10.00 | 10.06 | 9.56 | 9.80 | 11.60M |
| Oct 12, 2026 | 10.59 | 10.62 | 10.05 | 10.12 | 11.06M |
| Oct 9, 2026 | 9.95 | 10.80 | 9.87 | 10.51 | 18.66M |
| Oct 8, 2026 | 9.63 | 10.05 | 9.43 | 9.91 | 10.49M |
| Oct 7, 2026 | 9.50 | 9.93 | 9.33 | 9.75 | 11.78M |
| Oct 6, 2026 | 10.32 | 10.36 | 9.61 | 9.69 | 16.89M |
| Oct 5, 2026 | 10.76 | 10.81 | 10.12 | 10.38 | 16.87M |
| Oct 2, 2026 | 9.39 | 10.55 | 9.39 | 10.28 | 31.25M |
| Oct 1, 2026 | 9.28 | 9.40 | 9.07 | 9.28 | 12.31M |
| Sep 30, 2026 | 8.92 | 10.09 | 8.90 | 9.44 | 27.29M |
| Sep 29, 2026 | 8.52 | 8.88 | 8.52 | 8.83 | 8.37M |
| Sep 28, 2026 | 8.39 | 8.98 | 8.26 | 8.52 | 10.41M |
| Sep 25, 2026 | 8.76 | 8.84 | 8.41 | 8.44 | 5.82M |
| Sep 24, 2026 | 8.50 | 8.68 | 8.31 | 8.64 | 8.98M |
| Sep 23, 2026 | 9.26 | 9.29 | 8.60 | 8.63 | 13.95M |
| Sep 22, 2026 | 8.45 | 9.48 | 8.37 | 9.29 | 21.13M |
| Sep 21, 2026 | 8.72 | 8.87 | 8.26 | 8.45 | 12.24M |
| Sep 18, 2026 | 8.46 | 8.53 | 8.20 | 8.48 | 18.43M |
About ImmunityBio
ImmunityBio (IBRX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1326110.
IBRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Richard Adcock | CEO & President | Feb 24, 2026 |
| Michael D Blaszyk | Director | Jun 10, 2026 |
| Wesley Clark | Director | Jun 10, 2026 |
| Cheryl Cohen | Director | Jul 6, 2026 |
| Linda Maxwell | Director | Jun 10, 2026 |
| Patrick Soon-Shiong | See remarks | Apr 2, 2026 |
| Christobel Selecky | Director | Jul 6, 2026 |
| Barry J. Simon | Director | Jun 26, 2026 |
| Bruce Wendel | Director | Jun 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Richard Adcock | CEO & President | Feb 24, 2026 |
| Regan J Lauer | Chief Accounting Officer | Feb 24, 2026 |
| Patrick Soon-Shiong | See remarks | Apr 2, 2026 |
| David C. Sachs | Chief Financial Officer | Feb 24, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Cheryl Cohen | Sale | 131,210 | $9.50 |
| Jul 1, 2026 | Christobel Selecky | Sale | 159,478 | $9.02 |
| Jun 30, 2026 | Christobel Selecky | Sale | 1,000 | $9.00 |
| Jun 29, 2026 | Christobel Selecky | Sale | 95,722 | $9.01 |
| Jun 24, 2026 | Barry J. Simon | Sale | 25,000 | $7.88 |
| Jun 4, 2026 | Barry J. Simon | Sale | 23,033 | $7.18 |
| Feb 24, 2026 | Barry J. Simon | Sale | 75,000 | $12.01 |
| Feb 23, 2026 | Christobel Selecky | Sale | 25,000 | $10.00 |
| Feb 23, 2026 | Barry J. Simon | Sale | 165,000 | $10.25 |
| Feb 20, 2026 | Barry J. Simon | Sale | 10,000 | $9.25 |
| Jan 20, 2026 | Christobel Selecky | Sale | 25,000 | $7.51 |
| Jan 20, 2026 | Barry J. Simon | Sale | 75,000 | $7.88 |
| Jan 20, 2026 | Barry J. Simon | Sale | 76,967 | $6.54 |
| Jan 16, 2026 | Christobel Selecky | Sale | 50,000 | $5.00 |
IBRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $113.29M | $-351.40M | -0.38 | $-304.94M |
| Dec 31, 2024 | $14.74M | $-413.56M | -0.62 | $-391.24M |
| Dec 31, 2023 | $622.00K | $-583.20M | -1.15 | $-366.76M |
| Dec 31, 2022 | $240.00K | $-416.57M | -1.04 | $-337.51M |
| Dec 31, 2021 | — | $-346.79M | -0.89 | $-274.42M |
Latest balance sheet: total assets $628.50M, total liabilities $1.67B, cash $75.67M (as of Jun 30, 2026).
IBRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $6.95 |
| May 7, 2026 | 8-K Item 2.02 (results) | $7.76 |
| Apr 9, 2026 | 8-K Item 2.02 (results) | $7.48 |
| Feb 23, 2026 | 8-K Item 2.02 (results) | $9.83 |
| Jan 15, 2026 | 8-K Item 2.02 (results) | $3.95 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $2.15 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $2.41 |
| Jul 25, 2025 | 8-K Item 2.02 (results) | $2.86 |
| May 12, 2025 | 8-K Item 2.02 (results) | $2.36 |
| Apr 15, 2025 | 8-K Item 2.02 (results) | $2.78 |
| Mar 3, 2025 | 8-K Item 2.02 (results) | $2.85 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $4.95 |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)Repligen (RGEN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on IBRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.